- Home
- / Contineum Therapeutics
Contineum Therapeutics
Stock Price
$17.1
2024-10-29
Market Capitalization
$440.1 M
2024-10-29
Revenue
$50 M
FY, 2023
Contineum Therapeutics Summary
Company Summary
- Overview
- Contineum Therapeutics (formerly known as Pipeline Therapeutics) is a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small-molecule therapies for NI&I indications.
- Type
- Public
- Status
- Active
- Founded
- 2017
- HQ
- San Diego, CA, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
Peter T. Slover, Chief Financial Officer
Daniel S. Lorrain, Chief Science Officer
Stephen L. Huhn, Chief Medical Officer and Senior Vice President, Clinical Development
LocationsView all
1 location detected
San Diego, CA HQ
United States
10578 Science Center Dr #200
Contineum Therapeutics Financials
Summary Financials
- Net income (Q1, 2026)
- ($14.5M)
- Cash (Q1, 2026)
- $20.2M
- EBIT (Q1, 2026)
- ($16.9M)
- Enterprise value
- $426.9M